Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linagliptin 78-Week Open Label Extension in Type 2 Diabetes
NCT00736099Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2008
- Primary completion
- Dec 2010
- Modality
- Small Molecules
- Countries
- 32
01
Overview
A Phase 3 trial of linagliptin in type 2 diabetes mellitus (T2DM), sponsored by Boehringer Ingelheim. Started Aug 2008; status: completed.
02
Drugs
linagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00736099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00736099.